FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006235763> ?p ?o ?g. }

• W2006235763 abstract "Background: MP-470 is an orally bioavailable multi-targeted tyrosine kinase inhibitor specifically designed to be a potent inhibitor of mutant c-Kit and PDGFRα. MP-470 is also active as an inhibitor of DNA repair protein Rad51 following chemotherapy. MP-470 has shown synergistic activity with DNA damaging chemotherapy in several xenograft models and in a phase Ib combination study. Presented herein are final results from a MP-470 single agent first-in-man study. Methods: Adult pts with unresectable or metastatic solid tumor cancer refractory to standard therapies or for which no standard therapy exists, adequate bone marrow, renal and hepatic function, and KPS 70 were eligible. The study followed an Accelerated Titration Design. Starting dose was 100 mg/day and dose escalation was based on the modified Fibonacci sequence. Objectives of the study include evaluating the safety profile of MP-470, estimating the therapeutic response rate, and characterizing its pharmacokinetic (PK) profile. Results: Twenty-two pts with a median age of 56 yrs (range, 18-86); 13 M/9 F were enrolled and received MP-470 100-1500 mg/day of the dry powder (DP) formulation for 1-6 (median, 2) 28-day cycles. Median number of prior chemotherapies was 3 (range, 0-11). A positive FDG-PET response was observed on Day 15 in a GIST pt (900 mg/day) who previously failed imatinib and sunitinib. Notably, the percent change in SUVmax from baseline in the pelvis, retrocrural and left lower lobe was reported at 32% (21.3 vs 14.5), 32% (10.5 vs 7.1), and 14% (7.8 vs 6.7), respectively. Related G1/G2 AEs included nausea, vomiting, abdominal distension, diarrhea, dysgeusia, dyspnea, anorexia, hyperkalemia, fatigue, anxiety, heartburn, and alopecia. Related G3/4 AEs included hyponatremia and anxiety. The highest dose reached was 500 mg TID with no DLTs observed. PK evaluation using non-compartmental analysis revealed lower Cmax and AUC with increasing dose. As a result, a lipid suspension (LP) formulation was developed and compared to the existing DP formulation in a single dose randomized, two-way cross-over study in HV. The objective of the study was to determine the relative bioavailability and safety of these two formulations. The LP formulation demonstrated a 6- and 2-fold increase in Cmax and AUC, respectively as compared to the DP formulation (AACR-NCI-EORTC, B209, 2009). Both formulations were well tolerated. Conclusions: The MP-470 DP formulation was well tolerated at doses up to 500 mg TID. A transient response in a highly refractory GIST patient was observed and as such warrants further investigation as a single agent in refractory GIST tumors. A phase 1b study is ongoing in combination with chemotherapy as an inhibitor of DNA repair protein Rad51. An LP formulation in a tocopherol-based vehicle provided improved overall exposure and will be further evaluated in future MP-470 clinical trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2749." @default.
• W2006235763 created "2016-06-24" @default.
• W2006235763 creator A5018041025 @default.
• W2006235763 creator A5020548821 @default.
• W2006235763 creator A5039840799 @default.
• W2006235763 creator A5041499324 @default.
• W2006235763 creator A5060992997 @default.
• W2006235763 creator A5087191740 @default.
• W2006235763 date "2010-04-15" @default.
• W2006235763 modified "2023-09-27" @default.
• W2006235763 title "Abstract 2749: MP-470, a dual inhibitor of mutant kinases (c-KIT and PDGFRα) and DNA repair protein Rad 51. Final results from a first-in-man single agent study" @default.
• W2006235763 doi "https://doi.org/10.1158/1538-7445.am10-2749" @default.
• W2006235763 hasPublicationYear "2010" @default.
• W2006235763 type Work @default.
• W2006235763 sameAs 2006235763 @default.
• W2006235763 citedByCount "1" @default.
• W2006235763 countsByYear W20062357632021 @default.
• W2006235763 crossrefType "proceedings-article" @default.
• W2006235763 hasAuthorship W2006235763A5018041025 @default.
• W2006235763 hasAuthorship W2006235763A5020548821 @default.
• W2006235763 hasAuthorship W2006235763A5039840799 @default.
• W2006235763 hasAuthorship W2006235763A5041499324 @default.
• W2006235763 hasAuthorship W2006235763A5060992997 @default.
• W2006235763 hasAuthorship W2006235763A5087191740 @default.
• W2006235763 hasConcept C112705442 @default.
• W2006235763 hasConcept C121608353 @default.
• W2006235763 hasConcept C126322002 @default.
• W2006235763 hasConcept C126894567 @default.
• W2006235763 hasConcept C142424586 @default.
• W2006235763 hasConcept C143998085 @default.
• W2006235763 hasConcept C2776694085 @default.
• W2006235763 hasConcept C2777583451 @default.
• W2006235763 hasConcept C2778729363 @default.
• W2006235763 hasConcept C2778820342 @default.
• W2006235763 hasConcept C2779490328 @default.
• W2006235763 hasConcept C71924100 @default.
• W2006235763 hasConcept C86803240 @default.
• W2006235763 hasConcept C87355193 @default.
• W2006235763 hasConcept C90924648 @default.
• W2006235763 hasConcept C98274493 @default.
• W2006235763 hasConceptScore W2006235763C112705442 @default.
• W2006235763 hasConceptScore W2006235763C121608353 @default.
• W2006235763 hasConceptScore W2006235763C126322002 @default.
• W2006235763 hasConceptScore W2006235763C126894567 @default.
• W2006235763 hasConceptScore W2006235763C142424586 @default.
• W2006235763 hasConceptScore W2006235763C143998085 @default.
• W2006235763 hasConceptScore W2006235763C2776694085 @default.
• W2006235763 hasConceptScore W2006235763C2777583451 @default.
• W2006235763 hasConceptScore W2006235763C2778729363 @default.
• W2006235763 hasConceptScore W2006235763C2778820342 @default.
• W2006235763 hasConceptScore W2006235763C2779490328 @default.
• W2006235763 hasConceptScore W2006235763C71924100 @default.
• W2006235763 hasConceptScore W2006235763C86803240 @default.
• W2006235763 hasConceptScore W2006235763C87355193 @default.
• W2006235763 hasConceptScore W2006235763C90924648 @default.
• W2006235763 hasConceptScore W2006235763C98274493 @default.
• W2006235763 hasLocation W20062357631 @default.
• W2006235763 hasOpenAccess W2006235763 @default.
• W2006235763 hasPrimaryLocation W20062357631 @default.
• W2006235763 hasRelatedWork W1992478608 @default.
• W2006235763 hasRelatedWork W1995130371 @default.
• W2006235763 hasRelatedWork W1996796153 @default.
• W2006235763 hasRelatedWork W2012435258 @default.
• W2006235763 hasRelatedWork W2013294240 @default.
• W2006235763 hasRelatedWork W2015455969 @default.
• W2006235763 hasRelatedWork W2039363762 @default.
• W2006235763 hasRelatedWork W2067188144 @default.
• W2006235763 hasRelatedWork W2069619048 @default.
• W2006235763 hasRelatedWork W2073583876 @default.
• W2006235763 hasRelatedWork W2076670881 @default.
• W2006235763 hasRelatedWork W2197868217 @default.
• W2006235763 hasRelatedWork W2268219878 @default.
• W2006235763 hasRelatedWork W2278109184 @default.
• W2006235763 hasRelatedWork W2332623013 @default.
• W2006235763 hasRelatedWork W2404021175 @default.
• W2006235763 hasRelatedWork W2522753800 @default.
• W2006235763 hasRelatedWork W2799418453 @default.
• W2006235763 hasRelatedWork W3083292496 @default.
• W2006235763 hasRelatedWork W3199095368 @default.
• W2006235763 isParatext "false" @default.
• W2006235763 isRetracted "false" @default.
• W2006235763 magId "2006235763" @default.
• W2006235763 workType "article" @default.